Business & Regulation

As long as payers recognize the value of a curative treatment and manufacturers are flexible with payment plans, patients will have access to ATMPs.

For manufacturers, educating stakeholders, generating evidence and putting the patient first are key to getting value based contracts right.

Scott Gottlieb prepares to leave the FDA after accomplishing much.

Research and development tax reliefs are available for businesses in many countries, but some companies are not taking advantage.

A recently published report shows how the European Commission has protected patients against anticompetitive practices over the last decade.

Are healthcare systems and manufacturers ready to embrace evidence-based pricing to lessen the impact of upfront costs of advanced therapies?

Angela Osborne has created her own space in the industry and is helping the cell and gene therapy industry bloom.

EU will allow companies to carry out QC testing in the UK after a "no deal" Brexit, at least under certain conditions and for a limited time.

Nick Crabb explains the UK’s health technology assessment agency's (NICE's) approach to cell and gene therapies.

If you or your supplier are working with animal-derived components, you run the risk of exposing patients to dangerous contaminations.